Loading clinical trials...
Loading clinical trials...
A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix
Conditions
Interventions
Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001
Laboratory Biomarker Analysis
Locations
24
United States
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
Los Angeles County-USC Medical Center
Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
UCSF Medical Center-Mount Zion
San Francisco, California, United States
Start Date
May 23, 2011
Primary Completion Date
October 2, 2018
Completion Date
October 2, 2018
Last Updated
September 11, 2020
NCT05639972
NCT06654011
NCT02466971
NCT04622670
NCT04580771
NCT02257528
Lead Sponsor
Gynecologic Oncology Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions